Published in Tetrahedron Asymmetry on July 04, 2005
Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology (2002) 3.79
The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci (1991) 3.07
Monoamine transporters and psychostimulant drugs. Eur J Pharmacol (2003) 2.60
Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol (2002) 2.54
Cocaine, reward, movement and monoamine transporters. Mol Psychiatry (2002) 1.59
Cocaine mechanisms: enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions. Neuroscience (2002) 1.26
[3H]nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J Pharmacol Exp Ther (1992) 1.23
Relationship between self-administration of amphetamine and monoamine receptors in brain: comparison with cocaine. J Pharmacol Exp Ther (1989) 1.21
Self-administration of cocaine analogs by rats. Psychopharmacology (Berl) (1999) 1.17
The discriminative stimulus effects of cocaine in pigeons. J Pharmacol Exp Ther (1993) 1.03
A novel and facile preparation of bremazocine enantiomers through optically pure N-norbremazocines. Bioorg Med Chem (2004) 1.00
Stimulant and reinforcing effects of cocaine in monoamine transporter knockout mice. Eur J Pharmacol (2003) 1.00
Clinical efficacy of reboxetine in major depression. J Clin Psychiatry (2000) 0.97
Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. Ann Pharmacother (2000) 0.96
Efficient, stereoselective synthesis of trans-2,5-disubstituted morpholines. Org Lett (2004) 0.89
Asymmetric synthesis of (+)-(S,S)-reboxetine via a new (S)-2-(hydroxymethyl)morpholine preparation. Org Lett (2005) 0.89
Cocaine-like discriminative stimulus effects of heroin: modulation by selective monoamine transport inhibitors. J Pharmacol Exp Ther (2004) 0.88
Unexpected catalyst for Wittig-type and dehalogenation reactions. J Org Chem (2002) 0.83
Stereoselective and species-dependent kinetics of reboxetine in mouse and rat. Chirality (1995) 0.81
Studying the neurobiology of stimulant and alcohol abuse and dependence in genetically manipulated mice. Behav Pharmacol (2002) 0.81
Discovery and structure-activity relationships of novel selective norepinephrine and dual serotonin/norepinephrine reuptake inhibitors. Bioorg Med Chem Lett (2005) 0.80
Chiral synthesis of (2S,3S)-2-(2-morpholin-2-yl-2-phenylmethoxy)phenol. Chirality (2004) 0.79
Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab (2012) 2.76
Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. J Med Chem (2005) 2.13
Structure-based design of potent non-peptide MDM2 inhibitors. J Am Chem Soc (2005) 2.12
1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem (2006) 1.88
Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther (2009) 1.88
Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology (2004) 1.71
Proteolytic activity monitored by fluorescence resonance energy transfer through quantum-dot-peptide conjugates. Nat Mater (2006) 1.66
Hydrolytic reactivity trends among potential prodrugs of the O2-glycosylated diazeniumdiolate family. Targeting nitric oxide to macrophages for antileishmanial activity. J Med Chem (2008) 1.62
A facile method for the preparation of deuterium labeled salvinorin A: synthesis of [2,2,2-2H3]-salvinorin A. Bioorg Med Chem Lett (2004) 1.60
Reversal of pancreatitis-induced pain by an orally available, small molecule interleukin-6 receptor antagonist. Pain (2010) 1.58
Synthetic studies of neoclerodane diterpenoids from Salvia splendens and evaluation of Opioid Receptor affinity. Tetrahedron (2008) 1.53
N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. J Med Chem (2009) 1.52
Assessment of the kappa opioid agonist, salvinorin A, as a punisher of drug self-administration in monkeys. Psychopharmacology (Berl) (2014) 1.48
A hybrid quantum dot-antibody fragment fluorescence resonance energy transfer-based TNT sensor. J Am Chem Soc (2005) 1.41
Synthesis of salvinorin A analogues as opioid receptor probes. J Nat Prod (2006) 1.39
Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration. Neuropsychopharmacology (2007) 1.38
In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J Pharmacol Exp Ther (2011) 1.37
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A. J Nat Prod (2006) 1.36
Reactive oxygen and targeted antioxidant administration in endothelial cell mitochondria. J Biol Chem (2006) 1.35
Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol (2012) 1.32
PABA/NO as an anticancer lead: analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity. J Med Chem (2006) 1.30
Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. J Pharmacol Exp Ther (2005) 1.29
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: selective modification of the furan ring. Bioorg Med Chem Lett (2006) 1.29
Relationship between injection duration, transporter occupancy and reinforcing strength of cocaine. Eur J Pharmacol (2004) 1.29
Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev (2011) 1.26
Synthesis of rac-(1R,4aR,9aR)-2-methyl-1,3,4,9a-tetrahydro-2H-1,4a-propanobenzofuro[2,3-c]pyridin-6-ol. An unusual double rearrangement leading to the ortho- and para-f oxide-bridged phenylmorphan isomers. Org Biomol Chem (2004) 1.25
Delay discounting of saccharin in rhesus monkeys. Behav Processes (2009) 1.25
Effects of clomipramine on self-control choice in Lewis and Fischer 344 rats. Pharmacol Biochem Behav (2005) 1.24
A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence. Synapse (2007) 1.24
A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor. J Med Chem (2004) 1.24
Salvinicins A and B, new neoclerodane diterpenes from Salvia divinorum. Org Lett (2005) 1.23
The reinforcing efficacy of psychostimulants in rhesus monkeys: the role of pharmacokinetics and pharmacodynamics. J Pharmacol Exp Ther (2003) 1.21
Salvinorin A: allosteric interactions at the mu-opioid receptor. J Pharmacol Exp Ther (2006) 1.21
A virtual screen for diverse ligands: discovery of selective G protein-coupled receptor antagonists. J Am Chem Soc (2008) 1.20
Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Biochem Pharmacol (2007) 1.20
Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend (2010) 1.20
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues. J Med Chem (2007) 1.18
Development of functionally selective, small molecule agonists at kappa opioid receptors. J Biol Chem (2013) 1.17
Estimating the relative reinforcing strength of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) and its isomers in rhesus monkeys: comparison to (+)-methamphetamine. Psychopharmacology (Berl) (2006) 1.15
Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates. Synapse (2005) 1.13
The generalized matching law as a predictor of choice between cocaine and food in rhesus monkeys. Psychopharmacology (Berl) (2002) 1.13
Analyzing nanomaterial bioconjugates: a review of current and emerging purification and characterization techniques. Anal Chem (2011) 1.13
Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid. J Pharmacol Exp Ther (2008) 1.12
Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans. J Pharmacol Exp Ther (2006) 1.12
R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biol Psychiatry (2012) 1.12
Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats. Pharmacol Biochem Behav (2009) 1.11
Investigation of Zr(IV) and 89Zr(IV) complexation with hydroxamates: progress towards designing a better chelator than desferrioxamine B for immuno-PET imaging. Chem Commun (Camb) (2012) 1.11
Sensing caspase 3 activity with quantum dot-fluorescent protein assemblies. J Am Chem Soc (2009) 1.09
Adamantyl cannabinoids: a novel class of cannabinergic ligands. J Med Chem (2005) 1.09
Kappa opioids as potential treatments for stimulant dependence. AAPS J (2005) 1.08
Effects of dose and infusion delay on cocaine self-administration choice in rhesus monkeys. Psychopharmacology (Berl) (2003) 1.08
Synthesis of an energetic nitrate ester. Angew Chem Int Ed Engl (2008) 1.07
Gedunin, a novel hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships. J Med Chem (2008) 1.07
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: exploration of the 1-position. Bioorg Med Chem Lett (2007) 1.07
Maltose-binding protein: a versatile platform for prototyping biosensing. Curr Opin Biotechnol (2006) 1.05
The reinforcing efficacy of the dopamine reuptake inhibitor 2beta-propanoyl-3beta-(4-tolyl)-tropane (PTT) as measured by a progressive-ratio schedule and a choice procedure in rhesus monkeys. J Pharmacol Exp Ther (2002) 1.05
Conformationally constrained analogues of diacylglycerol. 29. Cells sort diacylglycerol-lactone chemical zip codes to produce diverse and selective biological activities. J Med Chem (2008) 1.04
Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem (2008) 1.03
Kappa opioids and the modulation of pain. Psychopharmacology (Berl) (2010) 1.03
Chemistry of the diazeniumdiolates. O- versus N-alkylation of the RNH[N(O)NO](-) ion. J Am Chem Soc (2004) 1.02
Delay discounting in rhesus monkeys: equivalent discounting of more and less preferred sucrose concentrations. Learn Behav (2012) 1.02
Determination of Salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.01
Azide-tetrazole equilibrium of C-6 azidopurine nucleosides and their ligation reactions with alkynes. J Org Chem (2010) 1.01
Uptake, distribution and diffusivity of reactive fluorophores in cells: implications toward target identification. Mol Pharm (2010) 1.00
Self-administration of mixtures of fenfluramine and amphetamine by rhesus monkeys. Pharmacol Biochem Behav (2006) 1.00
Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors. J Am Chem Soc (2013) 1.00
Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend (2011) 1.00
A reduced rate of in vivo dopamine transporter binding is associated with lower relative reinforcing efficacy of stimulants. Neuropsychopharmacology (2006) 0.99
Role of the increased noradrenergic neurotransmission in drug self-administration. Drug Alcohol Depend (2005) 0.99
Behavioral evaluation of modafinil and the abuse-related effects of cocaine in rhesus monkeys. Exp Clin Psychopharmacol (2010) 0.99
Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacology (Berl) (2012) 0.97
Potential Drug Abuse Therapeutics Derived from the Hallucinogenic Natural Product Salvinorin A. Medchemcomm (2011) 0.97
(+/-)-Nantenine analogs as antagonists at human 5-HT(2A) receptors: C1 and flexible congeners. Bioorg Med Chem Lett (2009) 0.97
Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor. Synapse (2010) 0.97
Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.97